ArticleChinese journal of integrative medicine2026
Aconitine from Aconiti Lateralis Radix Praeparata (Fuzi) Suppresses Intrahepatic Cholangiocarcinoma via TOP2A: A Study Combining Machine Learning with Functional Validation.
Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo elucidate the therapeutic potential and mechanisms of Fuzi (Aconiti Lateralis Radix Praeparata) against intrahepatic cholangiocarcinoma (ICC).
methodsFuzi-related targets were obtained from TCMSP, HERB, and ETCM databases, and ICC-related differentially expressed genes were retrieved from Gene Expression Omnibus. Common hub targets were identified using network pharmacology and machine learning, followed by functional enrichment and immune infiltration analyses. Effects of aconitine, a major alkaloid of Fuzi, were validated in RBE cells using qPCR, Western blot, Transwell assays, and flow cytometry.
resultsThirty-six common genes were identified, mainly enriched in metabolic and cancer-related pathways. Topoisomerase II alpha (TOP2A) and alpha1A-adrenergic receptor (ADRA1A) were identified as hub genes with high diagnostic value (area under curve>0.98). High TOP2A expression was linked to poor disease-free survival. Several immune cells, including regulatory T cells, showed altered infiltration in ICC and correlated with hub gene expression. Aconitine inhibited the proliferation, migration, and invasion of RBE cells in a dose- and time-dependent manner (P<0.05 or P<0.01). It also induced G
conclusionTOP2A was identified as Fuzi's potential therapeutic target in ICC, where its compound aconitine exerts antitumor effects by downregulating TOP2A, providing novel mechanistic insights and targeted therapy potential.
Indexed as
Identifiers
42448944What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.